Enoxaparin sodium
As of the edition of 20 October 2026, Enoxaparin sodium is an oligosaccharide: marketed, first approved in 1987 (FR); acts on SERPINC1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2009
- Kind
- Oligosaccharide
- Brand name
- Lovenox (preservative Free)
- First approved
- 3 April 1987 (FR)
- Approvals on record
- 40 in 6 regions
- Holder of the most recent approval
- FARMA VISION IMPORTAÇÃO E EXPORTAÇÃO DE MEDICAMENTOS LTDA; 11 holders in all
- Withdrawn from market
- 15 September 2019 (in some regions)
- Registered trials
- 184, 26 stopped early
- Disease areas
- Heart and blood vessels; Lungs and airways; Cancer; Infections; Urinary and reproductive; Blood and lymph
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route B because of this drug.
Companies on route B for this drug
In the product3 companies are on route B because of Enoxaparin sodium.
See the 3 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SERPINC1 | Antithrombin-III | P01008 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 36 | 20 | 3 | 5 |
| Phase 1 | 15 | 15 | 0 | 0 |
| Phase 2 | 34 | 23 | 3 | 5 |
| Phase 3 | 54 | 30 | 6 | 10 |
| Phase 4 | 45 | 25 | 7 | 6 |
| All trials | 184 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Sanofi | Applicant and Lead sponsor of trials | 1988 to now |
| Blau Farmaceutica | Applicant | 2009 to now |
| Eurofarma Laboratorios | Later holder and Lead sponsor of trials | 2009 to now |
| Cristália Produtos Químicos Farmacêuticos Ltda | Later holder and Lead sponsor of trials | 2009 to now |
| Aché Laboratórios Farmacêuticos | Later holder | 2021 to now |
| Baxter Healthcare | Applicant | 2023 to now |